R&D: Diagnosis & Treatments
There appears to be no effect of Ivermectin on time to resolution of symptoms among adults with mild COVID-19. A double-blind randomized control trial conducted at a single site in Cali, Columbia by researchers affiliated with multiple medical institutions in Columbia included 476 adult patients with mild COVID-19 disease and symptoms for ≤ 7 days between July 15 and November 30, 2020 to receive either ivermectin 300 g/kg/day (n= 200) for 5 days or placebo (n=200). The median time to resolution of symptoms was 10 days for ivermectin (IQR, 9-13) compared to 12 days in placebo group (IQR, 9-13) (Hazard ratio, 1.07 (95% CI, 0.87 to 1.32), p = 0.53), however there was no statistically significant difference between groups. Resolved symptoms were noted in 82% of ivermectin group and 79% of placebo group by Day 21. There was no significant improvement of time to resolution of symptoms with the use of ivermectin compared to placebo, thus this study does not support ivermectin use for mild COVID-19 infection, although larger studies may be necessary to determine use for other clinically relevant outcomes.